Employees: 4,970
Size Entero Healthcare Solutions (ENTERO.NS) is an India Health Care company (Medical Distributors) with a market value of $925M, the 626th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,986 on 18 Nov 2026.
Performance Over six months the shares gained 60.1%, against -3.7% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 34.8% over the last twelve months (peer median +4.4%); the operating margin is 4.1% (peer median 1.9%).
Valuation It trades at 47.7× forward earnings against a peer median of 14.6× (most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +30%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points below its cost of capital (9.2% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹76.4B | ₹65.9B | ₹51.0B | ₹39.2B | ₹33.0B |
| Revenue growth | — | +29% | +30% | +19% | — |
| Gross profit | ₹5.22B | ₹3.80B | ₹2.48B | ₹1.69B | ₹1.10B |
| EBITDA | ₹3.61B | ₹2.68B | ₹1.72B | ₹1.12B | ₹640M |
| Net income | ₹1.39B | ₹1.15B | ₹948M | ₹391M | -₹116M |
| Free cash flow | n/a | ₹17.8M | -₹916M | -₹986M | -₹892M |
| Capital expenditure | n/a | ₹675M | ₹113M | ₹54.2M | ₹55.2M |
| Total debt | ₹9.04B | ₹6.77B | ₹3.85B | ₹3.38B | ₹4.38B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ENTERO.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +32.1% | -3.1% | highest of 21 |
| 6-month return | +60.1% | -3.7% | 3rd highest of 21 |
| Distance from 52-week high | -7.1% | -21.6% | 3rd highest of 21 |
| Revenue growth (TTM) | +34.8% | +4.4% | highest of 21 |
| Operating margin | 4.1% | 1.9% | 7th highest of 21 |
| Forward P/E | 47.7× | 14.6× | most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 24.7% | -1.2% | 2nd most demanding of 16 |
| Growth delivered (Del g) | +29.9% | +5.7% | highest of 16 |
| Hurdle (Req g minus delivered) | -5.3 pp | -6.3 pp | 8th most demanding of 16 |
| ROIC minus cost of capital | -0.4 pp | +0.0 pp | 10th lowest of 21 |
| Net debt / EBITDA | 1.9× | 0.2× | 3rd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 47.7× | 24.7% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 7.7× | 17.0% | +12.4% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 21.1× | -1.0% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 9.5× | -9.7% | +6.0% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 15.3× | 5.3% | +8.1% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 12.0× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | n/a | -1.6% | +1.0% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | n/a | 13.1% | +7.5% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | n/a | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | n/a | n/a | n/a |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | n/a | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | n/a | 58.3% | -7.8% |
| Excelsior Medical 4104.TW | Taiwan | $404M | +5% | +11% | 8% | n/a | -1.2% | +5.7% |